H-1337

H-1337 is a multi-kinase inhibitor under development primarily for the treatment of glaucoma and ocular hypertension. It acts by inhibiting various protein kinases, including Rho-associated protein kinase (ROCK), mammalian target of rapamycin (mTOR), and Akt, which are involved in cellular signaling pathways that regulate intraocular pressure and vascular remodeling. The drug has demonstrated efficacy in lowering intraocular pressure in animal models and early clinical trials. H-1337 is also being investigated for potential use in pulmonary hypertension due to its effects on vascular smooth muscle proliferation and vasodilation. The compound was first synthesized by D.Western Therapeutics Institute, which leads its development alongside Allysta Pharmaceuticals[1][3][4][5].